Tango Therapeutics Inc. has released a corporate presentation highlighting its advancements in targeted therapies for oncology. The presentation outlines significant opportunities to treat multiple common cancers, focusing on potential best-in-class oral PRMT5 inhibitors and a first-in-class oral CoREST inhibitor. Key indications include lung and pancreatic cancers, with notable prospects in MTAP-deleted and STK11-mutated cancers. The presentation also provides information on ongoing clinical trials and updates expected in the second half of 2025. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.